+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antiparasitic Drugs Market by Drug Class, Veterinary - Global Forecast to 2030- Product Image
Antiparasitic Drugs Market by Drug Class, Veterinary - Global Forecast to 2030- Product Image
Sale

Antiparasitic Drugs Market by Drug Class, Veterinary - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715672
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antiparasitic Drugs Market grew from USD 21.12 billion in 2024 to USD 22.18 billion in 2025. It is expected to continue growing at a CAGR of 4.78%, reaching USD 27.95 billion by 2030.

Unlocking the Future of Antiparasitic Therapies

Antiparasitic drugs lie at the heart of safeguarding animal health and food security worldwide. Advances in molecular biology have spurred innovation in drug design, while rising awareness of zoonotic threats underscores the urgency of effective parasite control. Recent breakthroughs in novel chemotypes and combination therapies have not only expanded the therapeutic arsenal but also reshaped expectations for efficacy and safety.

Against this backdrop, market stakeholders-from biotech pioneers to established veterinary pharmaceutical companies-must navigate a complex web of regulatory frameworks, shifting consumption patterns, and evolving resistance profiles. Decision-makers require an integrated perspective that synthesizes technological trends, policy developments, and end-user behaviors to craft winning strategies.

This executive summary presents a panoramic view of the current landscape and its trajectory through 2025. By highlighting transformative shifts, tariff influences, segmentation dynamics, regional nuances, and leading corporate maneuvers, we equip you with a concise yet robust foundation. The subsequent sections distill critical insights and translate them into strategic imperatives, ensuring you remain at the forefront of this vital market.

Shifting Paradigms Reshape Antiparasitic Treatment Dynamics

The antiparasitic domain is in the midst of a profound metamorphosis. Next-generation macrocyclic lactones are exhibiting unprecedented spectrum coverage, while entirely new chemical classes such as amino-acetonitrile derivatives are proving effective against resistant nematode strains. Concurrently, digital health platforms are facilitating precision dosing and real-time monitoring of treatment outcomes, heralding a new era of data-driven therapeutic interventions.

Regulators have responded by streamlining approval pathways for drugs addressing critical unmet needs, accelerating access but also intensifying competitive pressure. At the same time, sustainability considerations are prompting manufacturers to optimize production processes and minimize environmental footprints, driving investment in green chemistry.

Emerging players are challenging incumbents by forging partnerships across biotech, informatics, and formulation science, thus creating multidisciplinary solutions that extend beyond mere efficacy. These alliances are redefining value propositions, with combination therapies, long-acting injectables, and oral sustained-release formulations gaining traction. As a result, the market is shifting from a focus on standalone products to comprehensive parasite management ecosystems that integrate diagnostics, therapeutics, and post-treatment analytics.

Navigating the Implications of New US Tariff Policies

Effective January 2025, the United States implemented revised tariff structures that affect a wide array of active pharmaceutical ingredients and finished formulations within the antiparasitic segment. The cumulative impact of these duties has introduced additional cost burdens on certain imported drug classes, particularly those derived from benzimidazole and macrocyclic lactone platforms. Pass-through of these costs is evident at various distribution nodes, from bulk API suppliers to frontline veterinary practitioners.

The heightened duties have prompted supply chain recalibrations, with some manufacturers establishing alternative sourcing arrangements in tariff-exempt jurisdictions or seeking in-country API production capabilities. Meanwhile, price adjustments in end markets have influenced procurement contracts and reimbursement negotiations, especially in cash-constrained veterinary clinics.

Despite these headwinds, the market has adapted through localized partnerships and selective product reformulations that circumvent the steepest levies. Key exporters are realigning their product portfolios, prioritizing high-margin novel entities less sensitive to duty fluctuations. In response, downstream stakeholders are renegotiating supply agreements to secure stable pricing and maintain service continuity, underscoring the sector’s resilience and agility in the face of policy changes.

Decoding Key Segmentation Patterns in Antiparasitic Markets

A comprehensive segmentation analysis reveals how distinct drug classes and veterinary applications are shaping market dynamics. When examining the market based on drug class, amino-acetonitrile compounds such as monepantel are emerging as growth drivers due to their novel mode of action against resistant parasites, while benzimidazoles-spanning key molecules like albendazole, fenbendazole, mebendazole, oxibendazole, and thiabendazole-remain foundational to treatment protocols thanks to their broad-spectrum efficacy. Macrocyclic lactones including abamectin, doramectin, eprinomectin, and ivermectin continue to command significant share by virtue of their proven safety profiles and established distribution channels. Concurrently, spiroindoles represented by derquantel are carving out niches where combination regimens enhance therapeutic outcomes.

Turning to the veterinary end-use perspective, antiparasitic demand within aquaculture is driven by fish and shrimp producers facing disease outbreaks, whereas companion animal care, encompassing both canine and feline segments, demands tailored formulations that balance palatability with potency. In livestock applications, cattle, poultry, and swine operations prioritize scalable intervention strategies that deliver rapid parasite clearance and minimize downtime. This layered segmentation underscores the importance of aligning product innovation and go-to-market approaches with the unique drivers, regulatory requirements, and economic margins inherent to each subsegment.

Regional Variations Unveil Diverse Market Trajectories

Geographic variation exerts a profound influence on both product adoption and regulatory complexity. In the Americas, a robust infrastructure and strong prevalence awareness have accelerated uptake of advanced therapeutic classes, supported by favorable reimbursement frameworks and active industry consortia that champion research collaboration. Meanwhile, Europe, Middle East & Africa presents a mosaic of regulatory regimes, where stringent environmental mandates coexist with elevated demand for innovative treatments in both companion and production animal settings.

Turning to the Asia-Pacific region, rapid industrialization of aquaculture and expansion of large-scale livestock operations are driving unparalleled growth in antiparasitic consumption. Here, competitive pricing remains paramount, prompting manufacturers to pursue cost-effective formulations and localized manufacturing partnerships. At the same time, rising standards of veterinary care in urbanized markets are fueling parallel growth in the companion animal segment, creating dual opportunities for differentiated therapeutic offerings.

Profiling Leading Innovators Driving Market Momentum

Leading corporations have adopted varied strategies to consolidate their positions and capitalize on emerging opportunities. Established pharmaceutical multinationals continue to bolster their pipelines through strategic acquisitions of niche biotech innovators, enabling accelerated entry into high-potential classes such as amino-acetonitrile derivatives and spiroindole-based combinations. At the same time, agile specialist firms are leveraging focused R&D investments and collaborative ventures to pioneer next-generation long-acting formulations, often in partnership with academic institutions and contract research organizations.

Moreover, several market incumbents have embraced digital transformation initiatives, deploying data analytics platforms to optimize field efficacy monitoring and post-launch safety surveillance. These capabilities not only reinforce regulatory compliance but also enhance customer engagement through value-added services. Joint ventures between API manufacturers and formulation specialists are further streamlining supply chains, ensuring consistency of quality and faster time-to-market for key products. Collectively, these strategic maneuvers underscore the sector’s commitment to both incremental improvement and bold innovation, setting the stage for sustained competitive advantage.

Strategic Roadmap for Industry Trailblazers

Industry leaders must adopt a multifaceted approach that aligns with evolving market realities. First, investing in platform technologies that facilitate rapid screening of novel chemotypes will accelerate pipeline diversification and mitigate resistance risks. Simultaneously, forging cross-sector partnerships-spanning biotech, diagnostics, and digital health-will enhance holistic treatment solutions and foster deeper customer integrations.

Next, optimizing supply chain resilience through geographic diversification of manufacturing and strategic API alliances is essential to counter tariff volatility and regulatory shifts. Organizations should also prioritize regulatory intelligence capabilities that anticipate policy changes across key regions, enabling proactive portfolio adjustments and expedited approvals. On the commercial front, tailoring value propositions to specific subsegments-whether targeting high-margin companion animal therapeutics or cost-sensitive aquaculture applications-will drive more effective customer engagement and sustainable revenue growth.

Lastly, embedding sustainability metrics into R&D and manufacturing processes will not only address environmental concerns but also unlock new partnership opportunities with eco-conscious stakeholders and grant bodies. By executing these initiatives in concert, industry participants can solidify their market leadership, enhance operational agility, and unlock long-term value creation.

Rigorous Methodology Underpinning Our Insights

This analysis draws upon a triangulated research design integrating primary interviews, secondary data synthesis, and quantitative modeling. Primary research involved in-depth discussions with senior executives across pharmaceutical manufacturers, veterinary practitioners, academic experts, and regulatory authorities, yielding qualitative insights into innovation drivers and market barriers. Secondary research encompassed a comprehensive review of peer-reviewed journals, patent filings, government publications, and technical white papers to map technological trajectories and regulatory trends.

Quantitative modeling techniques were employed to validate thematic conclusions, leveraging historical adoption rates, trade flow data, and pricing dynamics. Cross-verification processes ensured consistency and accuracy, with multiple rounds of data reconciliation and expert validation workshops informing the final interpretations. The methodology emphasizes transparency and rigor, providing stakeholders with confidence in the integrity of the results and the robustness of the strategic recommendations.

Converging Trends Point to a Resilient Future

The confluence of innovative drug classes, evolving veterinary practices, and regulatory recalibrations indicates that the antiparasitic drugs market is poised for resilient growth through 2025. Despite external pressures such as tariff shifts and environmental mandates, the sector’s agility-demonstrated by rapid formulation advancements and dynamic partnerships-ensures its ability to meet escalating global demand.

Furthermore, the granular segmentation insights reveal distinct growth levers across drug classes and end-use applications, highlighting where investments in R&D, manufacturing, and commercialization will yield the greatest returns. Regional disparities underscore the need for tailored market entry strategies and localized engagement models, while leading companies’ strategic moves illustrate the efficacy of integrated innovation roadmaps.

In sum, stakeholders equipped with these findings will be better positioned to navigate disruption, harness emerging opportunities, and deliver superior animal health outcomes. The market’s trajectory underscores a shift from transactional supply models to collaborative, ecosystem-based approaches that prioritize long-term value and shared success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Amino-Acetonitrile
      • Monepantel
    • Benzimidazoles
      • Albendazole
      • Fenbendazole
      • Mebendazole
      • Oxibendazole
      • Thiabendazole
    • Macrocyclic Lactones
      • Abamectin
      • Doramectin
      • Eprinomectin
      • Ivermectin
    • Spiroindoles
      • Derquantel
  • Veterinary
    • Aquaculture
      • Fish
      • Shrimp
    • Companion Animals
      • Canine
      • Feline
    • Livestock
      • Cattle
      • Poultry
      • Swine
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Elanco Animal Health Incorporated
  • Bayer AG
  • Ceva Santé Animale S.A.
  • Virbac S.A.
  • Dechra Pharmaceuticals PLC
  • Vetoquinol S.A.
  • Norbrook Laboratories Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antiparasitic Drugs Market, by Drug Class
8.1. Introduction
8.2. Amino-Acetonitrile
8.2.1. Monepantel
8.3. Benzimidazoles
8.3.1. Albendazole
8.3.2. Fenbendazole
8.3.3. Mebendazole
8.3.4. Oxibendazole
8.3.5. Thiabendazole
8.4. Macrocyclic Lactones
8.4.1. Abamectin
8.4.2. Doramectin
8.4.3. Eprinomectin
8.4.4. Ivermectin
8.5. Spiroindoles
8.5.1. Derquantel
9. Antiparasitic Drugs Market, by Veterinary
9.1. Introduction
9.2. Aquaculture
9.2.1. Fish
9.2.2. Shrimp
9.3. Companion Animals
9.3.1. Canine
9.3.2. Feline
9.4. Livestock
9.4.1. Cattle
9.4.2. Poultry
9.4.3. Swine
10. Americas Antiparasitic Drugs Market
10.1. Introduction
10.2. United States
10.3. Canada
10.4. Mexico
10.5. Brazil
10.6. Argentina
11. Europe, Middle East & Africa Antiparasitic Drugs Market
11.1. Introduction
11.2. United Kingdom
11.3. Germany
11.4. France
11.5. Russia
11.6. Italy
11.7. Spain
11.8. United Arab Emirates
11.9. Saudi Arabia
11.10. South Africa
11.11. Denmark
11.12. Netherlands
11.13. Qatar
11.14. Finland
11.15. Sweden
11.16. Nigeria
11.17. Egypt
11.18. Turkey
11.19. Israel
11.20. Norway
11.21. Poland
11.22. Switzerland
12. Asia-Pacific Antiparasitic Drugs Market
12.1. Introduction
12.2. China
12.3. India
12.4. Japan
12.5. Australia
12.6. South Korea
12.7. Indonesia
12.8. Thailand
12.9. Philippines
12.10. Malaysia
12.11. Singapore
12.12. Vietnam
12.13. Taiwan
13. Competitive Landscape
13.1. Market Share Analysis, 2024
13.2. FPNV Positioning Matrix, 2024
13.3. Competitive Analysis
13.3.1. Zoetis Inc.
13.3.2. Merck & Co., Inc.
13.3.3. Boehringer Ingelheim International GmbH
13.3.4. Elanco Animal Health Incorporated
13.3.5. Bayer AG
13.3.6. Ceva Santé Animale S.A.
13.3.7. Virbac S.A.
13.3.8. Dechra Pharmaceuticals PLC
13.3.9. Vetoquinol S.A.
13.3.10. Norbrook Laboratories Limited
14. ResearchAI
15. ResearchStatistics
16. ResearchContacts
17. ResearchArticles
18. Appendix
List of Figures
FIGURE 1. ANTIPARASITIC DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTIPARASITIC DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTIPARASITIC DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ANTIPARASITIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. ANTIPARASITIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIPARASITIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 62. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 63. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 64. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 65. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 66. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 67. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 68. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 69. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 72. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 73. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 74. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 75. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 115. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 117. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 118. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 119. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 120. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 121. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 122. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 124. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 126. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 127. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 128. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 129. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 130. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 131. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 132. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 142. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 144. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 145. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 146. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 147. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 148. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 149. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 150. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 151. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 153. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 154. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 155. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 156. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 157. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 158. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 159. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 187. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 189. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 190. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 191. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 192. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 193. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 194. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 195. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 205. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 207. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 208. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 209. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 210. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 211. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 212. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 213. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 214. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 216. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 217. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 218. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 219. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 220. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 221. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 241. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 242. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 243. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 244. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 245. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 246. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 247. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 248. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 249. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 250. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 252. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 253. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 254. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 255. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 256. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 257. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 258. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 268. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 270. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 271. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 272. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 273. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 274. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 275. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 276. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 277. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 279. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 280. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 281. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 282. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 283. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 284. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 285. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 305. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 306. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 307. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 308. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 309. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 310. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 311. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 312. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 313. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 314. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 315. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 316. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 317. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 318. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 319. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 320. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 321. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 322. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 323. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 324. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 325. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 326. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 327. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 328. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 329. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 330. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 331. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2030 (USD MILLION)
TABLE 339. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 340. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD MILLION)
TABLE 341. SOUTH KOREA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 342. SOUTH KOREA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2030 (USD MILLION)
TABLE 343. SOUTH KOREA ANTIPARASITIC DR

Companies Mentioned

The companies profiled in this Antiparasitic Drugs market report include:
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Elanco Animal Health Incorporated
  • Bayer AG
  • Ceva Santé Animale S.A.
  • Virbac S.A.
  • Dechra Pharmaceuticals PLC
  • Vetoquinol S.A.
  • Norbrook Laboratories Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 22.18 Billion
Forecasted Market Value ( USD ) by 2030 $ 27.95 Billion
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antiparasitic Drugs Market Report 2025 - Product Image

Antiparasitic Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Veterinary Dermatology Market by Route of Administration, Product Type (Antibacterial, Antifungal, Antiparasitic Drugs, Monoclonal Antibodies), Condition Type (Parasitic Infections, Infectious Diseases, Skin Cancer), Animal Type - Global Forecast to 2030 - Product Image

Veterinary Dermatology Market by Route of Administration, Product Type (Antibacterial, Antifungal, Antiparasitic Drugs, Monoclonal Antibodies), Condition Type (Parasitic Infections, Infectious Diseases, Skin Cancer), Animal Type - Global Forecast to 2030

  • Report
  • 385 Pages
  • Global
From
Anti-Infective Agents Market Size, Share & Trends Analysis Report By Type (Antibacterial, Antiviral, Antifungal & Antiparasitic), By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Anti-Infective Agents Market Size, Share & Trends Analysis Report By Type (Antibacterial, Antiviral, Antifungal & Antiparasitic), By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 130 Pages
  • Global
From
Veterinary Anti-infectives Market by Animal Type, Product Type, Route Of Administration, Distribution Channel, Dosage Form, Application - Global Forecast to 2030 - Product Image

Veterinary Anti-infectives Market by Animal Type, Product Type, Route Of Administration, Distribution Channel, Dosage Form, Application - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Animal Parasiticides Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Animal Parasiticides Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From

About the Antiparasitic Agent Market

The Antiparasitic Agent market is a subset of the Infectious Diseases Drugs market, which focuses on the development and sale of drugs used to treat parasitic infections. Antiparasitic Agents are used to treat a variety of parasitic infections, including malaria, schistosomiasis, and leishmaniasis. These drugs are typically administered orally, intravenously, or topically, depending on the type of infection. Antiparasitic Agents are often used in combination with other drugs to ensure the most effective treatment. The Antiparasitic Agent market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Sanofi, Pfizer, and Novartis. Other companies, such as Johnson & Johnson, Bayer, and AstraZeneca, also offer Antiparasitic Agents. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.